retatrutide triple agonist gip glp-1 glucagon phase 3 2025 40mg 🚨Breaking: Retatrutide's first Phase 3

New research indicates that maintaining meaningful weight loss after starting GLP-1-based therapies could play an important role in reducing the risk of multiple obesity-related diseases.

Inflammatory bowel diseases (IBD), including Crohns disease (CD) and ulcerative colitis (UC), are chronic, relapsing, intestinal inflammatory disorders with complex and yet unrevealed pathogenesis in which genetic, immunological, and environmental factors play a role

The results of a Phase II clinical trial have demonstrated significant weight reduction in overweight and obese adults

She was prediabetic, a condition in which blood sugar levels are higher than normal, and her doctor prescribed Ozempic to help her avoid developing diabetes